Thymalin is a polypeptide complex isolated from calf thymus through acid extraction, first developed in the USSR in the 1970s. It is a multi-peptide mixture containing short bioactive segments, including thymogen, vilon, and crystogen. Its primary actions are immune modulation, T cell differentiation, hematopoietic stem cell activation, and geroprotection. Thymalin is approved in Russia as an immune modulator and carries no FDA approval in the United States.

This lesson sits within the immune regulation track and distinguishes Thymalin, a broad blanket immunomodulator, from thymosin alpha-1, a more directed synthetic peptide that the two are frequently mistaken for.

Mechanism and component peptides

The composite nature of Thymalin reflects its active fragments. The EW dipeptide targets the ACE2 and CYSLTR1 genes and is described as reducing angiotensin-induced cytokine storm, drawing a parallel to how ARBs shift angiotensin II toward angiotensin 1-7. The KE dipeptide targets the CHUK gene of the NFKB pathway, stimulating cellular immunity, inducing CD4 and CD5 thymocyte expression, and influencing telomere length, IGF-1, FOXO-1, and TERT. The EDP tripeptide stimulates IL-1, IL-6, and TNF-alpha from macrophages and activates thymic epithelial cells.

Across these fragments, signaling runs through NFKB, ERK and mTOR, P70S6K, and STAT1 phosphorylation that is receptor-independent. The peptides can bind histones and influence epigenetic state, increasing euchromatin and decreasing heterochromatin in elderly lymphocytes. In the T cell compartment, Thymalin can activate hematopoietic stem cell differentiation into CD28 T lymphocytes and normalize CD3, CD4, and CD8 ratios.

Clinical evidence and application

The strongest evidence comes from six to eight year randomized controlled studies in elderly patients aged 60 to 88, where Thymalin was associated with a two to four times mortality reduction. Combined with epitalon, the effect increased further. In severe COVID-19, small observational studies reported halved hospital mortality alongside faster recovery of lymphocyte counts. The speaker notes no significant adverse effects observed across 25 years of clinical use.

Standard dosing described is 10 mg daily for 10 days, totaling a 100 mg course, given intramuscularly in the original protocols and more commonly subcutaneously in Western practice. Courses may be repeated several times yearly. Monitoring centers on CBC, T cell subsets, inflammatory markers including CRP and cytokine panels, immunoglobulins, and coagulation studies when indicated, with reassessment around two weeks and three to four months.

Key clinical points

• Thymalin is a calf-thymus polypeptide complex (EW, KE, and EDP fragments) that supports broad innate and adaptive immune modulation, distinct from the more targeted thymosin alpha-1.
• Reported evidence centers on two to four times mortality reduction in elderly cohorts over six to eight years and halved hospital mortality in small severe COVID-19 studies.
• Described dosing is 10 mg daily for 10 days (100 mg course), subcutaneous or intramuscular, repeatable a few times per year and combinable with epitalon.
• Suggested monitoring includes CBC, T cell subsets, CRP and cytokine panels, immunoglobulins, and coagulation studies when clinically indicated.
• Most data originate from Russia with limited Western randomized trials; cautions include active autoimmune disease, transplant, uncontrolled malignancy, and pregnancy or lactation.